Literature DB >> 30745134

Locally advanced breast cancer: Tumor-infiltrating lymphocytes as a predictive factor of response to neoadjuvant chemotherapy.

Leonardo Russo1, Anggela Maltese2, Luis Betancourt2, Gabriel Romero2, Daniela Cialoni2, Liliana De la Fuente2, Marianna Gutierrez2, Angela Ruiz3, Emperatriz Agüero3, Silvia Hernández3.   

Abstract

OBJECTIVE: To evaluate the pathologic response after neoadjuvant chemotherapy in patients with breast cancer according to the stromal tumor-infiltrating lymphocytes (TILs) as well as the evaluation of overall and disease-free survival according to TILs.
METHODS: A six years (2008-2013) review was done including patients with locally advanced breast cancer that received neoadjuvant therapy and then surgery. An evaluation of the percentage of TILs was done in the pretreatment biopsies and a correlation analysis and survival curves were done.
RESULTS: 187 patients were evaluated. The pathological complete response (pCR) in patients with TILs ≥30% was 58.5%, and in patients with TILs < 30% was 11% (p <0.001). An Odds Ratio of 8.85 was obtained in patients with TILs ≥30% to achieve a pCR. This relationship was seen in patients with HER2-enriched and triple-negative subtypes. No correlation between TILs and survival was obtained (OS: log-rank; p = 0.834; DFS: log-rank; p = 0.937).
CONCLUSIONS: The study of TILs is important because they represent an additional tool to predict the response to neoadjuvant treatment mostly in HER2-enriched and triple-negative subtypes of breast cancer.
Copyright © 2019 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

Entities:  

Keywords:  Breast cancer; Neoadjuvant treatment; Predictive factor; Stromal tumor infiltrating lymphocytes; TILs

Mesh:

Substances:

Year:  2019        PMID: 30745134     DOI: 10.1016/j.ejso.2019.01.222

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  9 in total

1.  Tumor-infiltrating lymphocytes benefit prediction of axillary pathologic response and prognostication of event-free survival in HER2-positive and biopsy-proven node-positive breast cancer treated with neoadjuvant therapy.

Authors:  Shiwei Liu; Shiyan Zeng; Li Xia; Miao Yu; Xin Zhang; Hong Yang; Juan Ji; Hao Dong; Jianhui Zhang; Purong Zhang
Journal:  Breast Cancer Res Treat       Date:  2020-11-09       Impact factor: 4.872

2.  Clinical and pathological response to neoadjuvant chemotherapy with different chemotherapy regimens predicts the outcome of locally advanced breast cancer.

Authors:  Shicong Tang; Ke Wang; Kai Zheng; Jiadong Liu; Hengyu Zhang; Mingjian Tan; Hongwan Li; Huimeng Li; Xin Tan; Dequan Liu; Rong Guo
Journal:  Gland Surg       Date:  2020-10

3.  Immune microenvironment changes induced by neoadjuvant chemotherapy in triple-negative breast cancers: the MIMOSA-1 study.

Authors:  Victor Sarradin; Amélie Lusque; Thomas Filleron; Florence Dalenc; Camille Franchet
Journal:  Breast Cancer Res       Date:  2021-05-26       Impact factor: 6.466

4.  Development and Validation of a Novel Model for Predicting Prognosis of Non-PCR Patients After Neoadjuvant Therapy for Breast Cancer.

Authors:  Yongqiang Yu; Si Wu; Hui Xing; Mengxue Han; Jinze Li; Yueping Liu
Journal:  Front Oncol       Date:  2021-09-01       Impact factor: 6.244

5.  Nab-paclitaxel and atezolizumab for the treatment of PD-L1-positive, metastatic triple-negative breast cancer: review and future directions.

Authors:  Jodi A Kagihara; Michelle Andress; Jennifer R Diamond
Journal:  Expert Rev Precis Med Drug Dev       Date:  2020-02-20

6.  Ki67 Index Changes and Tumor-Infiltrating Lymphocyte Levels Impact the Prognosis of Triple-Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy.

Authors:  Yihua Wang; Beige Zong; Yu Yu; Yu Wang; Zhenrong Tang; Rui Chen; Man Huang; Shengchun Liu
Journal:  Front Oncol       Date:  2021-06-21       Impact factor: 6.244

Review 7.  Pathophysiological Integration of Metabolic Reprogramming in Breast Cancer.

Authors:  Roberto Corchado-Cobos; Natalia García-Sancha; Marina Mendiburu-Eliçabe; Aurora Gómez-Vecino; Alejandro Jiménez-Navas; Manuel Jesús Pérez-Baena; Marina Holgado-Madruga; Jian-Hua Mao; Javier Cañueto; Sonia Castillo-Lluva; Jesús Pérez-Losada
Journal:  Cancers (Basel)       Date:  2022-01-10       Impact factor: 6.639

Review 8.  Molecular subtypes and precision treatment of triple-negative breast cancer.

Authors:  Shen Zhao; Wen-Jia Zuo; Zhi-Ming Shao; Yi-Zhou Jiang
Journal:  Ann Transl Med       Date:  2020-04

9.  Platelet-to-Lymphocyte Ratio Is Associated With Favorable Response to Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: A Study on 120 Patients.

Authors:  Sejdi Lusho; Xavier Durando; Marie-Ange Mouret-Reynier; Myriam Kossai; Nathalie Lacrampe; Ioana Molnar; Frederique Penault-Llorca; Nina Radosevic-Robin; Catherine Abrial
Journal:  Front Oncol       Date:  2021-07-20       Impact factor: 6.244

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.